Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2018312590-A1 · Nov 1, 2018 · US
US10709849B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10709849-B2 |
| Application number | US-201414897400-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 11, 2014 |
| Priority date | Jun 11, 2013 |
| Publication date | Jul 14, 2020 |
| Grant date | Jul 14, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
There is provided a guide 200 for contacting an injection device 110 with a user; the guide 200 having a first end 210 adapted to engage a housing 112 of the injection device 110 and a second end 220 adapted to engage the surface of a user's skin, wherein the guide 200 permits movement of the housing 112 towards the user's skin.
Opening claim text (preview).
The invention claimed is: 1. A guide for contacting an injection device with a user, the guide comprising: a first component including a first end adapted to engage a housing of the injection device, the first component including at least one ratchet tooth; a second component including a second end adapted to engage a surface of the user's skin, wherein the second component is movable with respect to the first component, and wherein the second component comprises an inner surface including a plurality of ratchet teeth disposed in series that engage the at least one ratchet tooth on the first component such that the housing moves towards the user's skin incrementally. 2. The guide of claim 1 , wherein the first end is open. 3. The guide of claim 1 or claim 2 , wherein the second end is open. 4. The guide of claim 1 , wherein the guide is cylindrical. 5. The guide of claim 1 , wherein the guide is formed as a frame. 6. The guide of claim 1 , wherein the guide is formed with a continuous external surface. 7. The guide of claim 1 , wherein the guide comprises at least one stabilising element at the second end which is adapted to project from the guide and stabilise the guide on the skin. 8. The guide of claim 7 , wherein the guide comprises three stabilising elements at the second end. 9. A kit comprising the guide of claim 1 and an automatic injection device having a housing. 10. The kit of claim 9 , wherein the housing has a distal end and the first end of the guide is adapted to engage the housing at the distal end. 11. The kit of claim 9 , wherein the housing has a first diameter and the first end is dimensioned to surround the first diameter. 12. The kit of claim 11 , wherein a portion of the housing has a second diameter which is larger than the first diameter and the first end is dimensioned to engage the portion of the housing having a second diameter. 13. The kit of claim 12 , wherein the second diameter portion comprises a ridge. 14. The kit of claim 9 , wherein the first end is integral to the housing of the injection device. 15. An injection device comprising: a housing adapted to receive a syringe having a discharge nozzle, the syringe being moveable in the housing on actuation of the injection device along a longitudinal axis from a retracted position in which the discharge nozzle is contained within the housing and an extended position in which the discharge nozzle of the syringe extends from the housing through an exit aperture at a distal end of the device; a sliding component which extends, when in a first position, from the aperture, and is movable towards the housing into a second, retracted, position; and a guide for contacting an injection device with a user; the guide comprising: a first component including a first end adapted to engage the housing, the first component including at least one ratchet tooth, a second component including a second end adapted to engage a surface of the user's skin, wherein the second component is movable with respect to the first component, and wherein the second component includes an inner surface having a plurality of ratchet teeth disposed in series that engage the at least one ratchet tooth on the first component such that the housing moves towards the user's skin incrementally. 16. A device according to claim 15 , further comprising: an actuator; and a drive adapted to be acted upon by the actuator and in turn act upon the syringe to advance it from its retracted position to its extended position and discharge its contents through the discharge nozzle. 17. A device according to claim 15 , wherein the sliding component is part of a locking mechanism moveable from an engaged position, when the sliding component is in its first position, to a disengaged position, when the sliding component is in its second position, and adapted to prevent actuation of the device when it is in its engaged position and permit actuation of the device when it is in its disengaged position. 18. A kit according to any one of claims 9 to 11 or 12 to 14 or an injection device according to any one of claims 15 to 17 , wherein the injection device contains a substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity. 19. A substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity, by delivery of said substance to a human subject using a kit according to any one of claims 9 to 11 or 12 to 14 or an injection device according to any one of claims 15 to 17 . 20. An injection device for use in the treatment or prevention rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity, by delivery of a substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, to a human subject by using the injection device, wherein the injection device is an injection device according to any one of claims 15 to 17 or is comprised in a kit according to any one of claims 9 to 11 or 12 to 14 .
Spring-loaded one-shot injectors with or without automatic needle insertion (multishot dosing syringes A61M5/31525, needle insertion only A61M5/3287) · CPC title
Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means · CPC title
Having specific accessories · CPC title
Release is possible only when device is pushed against the skin, e.g. using a trigger which is blocked or inactive when the device is not pushed against the skin · CPC title
preventing premature release, e.g. by making use of a safety lock · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.